(Q84684036)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

1 reference

Kaoru Takase

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Shigeru Ohno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Haruko Ideguchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Eiichi Uchio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mitsuhiro Takeno

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Yoshiaki Ishigatsubo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

9 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

Rheumatology International

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

243-245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19816689%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y

9 February 2020

exact match

0 references

cites work

Adalimumab: a new modality for Behçet's disease?

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

1 reference

12 December 2020

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

12 December 2020

Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience

1 reference

12 December 2020

Adalimumab for sight-threatening uveitis in Behçet's disease.

1 reference

12 December 2020

Behçet's disease: a new target for anti-tumour necrosis factor treatment

1 reference

12 December 2020

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

12 December 2020

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

1 reference

12 December 2020

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation

1 reference

12 December 2020

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

1 reference

12 December 2020

Biologics in the treatment of uveitis

1 reference

12 December 2020

Anti-TNF therapies in the management of acute and chronic uveitis

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020